Abnormalities of the HPA axis in affective disorders: Clinical subtypes and potential treatments

Acta Neuropsychiatrica

Volumn 18, Issue 5, 2006, Pages 193-209

  Porter, Richard J ^a   Gallagher, Peter ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Bipolar disorder; Cortisol; CRH; Depression; DHEA; Hypothalamic pituitary adrenal axis; Mifepristone

Indexed keywords

11BETA (1,3 BENZODIOXOL 5 YL) 17BETA HYDROXY 17ALPHA (1 PROPYNYL)ESTRA 4,9 DIEN 3 ONE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; AMINOGLUTETHIMIDE; ANTIDEPRESSANT AGENT; ARGIPRESSIN; CORTICOSTERONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DOPAMINE; FLUVOXAMINE; GLUCOCORTICOID ANTAGONIST; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ANTAGONIST; HYDROCORTISONE; KETOCONAZOLE; LORAZEPAM; METYRAPONE; MIFEPRISTONE; NEFAZODONE; PAROXETINE; PRASTERONE SULFATE; PSYCHOTROPIC AGENT; SEROTONIN; SEROTONIN AGONIST; STEROID HORMONE; STEROID RECEPTOR; UNCLASSIFIED DRUG;

ADRENAL DISEASE; ADRENAL FUNCTION; BIPOLAR DISORDER; CLINICAL TRIAL; COGNITION; DEPRESSIVE PSYCHOSIS; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG MECHANISM; HUMAN; HYPOPHYSIS DISEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MEDICAL LITERATURE; MOOD DISORDER; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; TREATMENT RESPONSE;

EID: 33750465869     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1111/j.1601-5215.2006.00152.x     Document Type: Review

References (191)

1. GIBBONS JL. Cortisol secretion rate in depressive illness. Arch Gen Psychiatry 1964;10:572-575.
2. VALE W, SPIESS J, RIVIER C, RIVIER J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981;213:1394-1397.
3. PLOTSKY PM. Pathways to the secretion of adrenocorticotropin: a view from the portal. J Neuroendocrinol 1991;3:1-9.
4. HOLSBOER F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 1999;33:181-214.
5. STEIGER A, HOLSBOER F. Neuropeptides and human sleep. Sleep 1997;20:1038-1052.
6. BEATO M. Gene regulation by steroid hormones. Cell 1989;56:335-344.
7. ANTONI FA. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol 1993;14:76-122.
8. TILDERS FJH, SCHMIDT ED, DE GOEIJ DCE. Phenotypic plasticity of CRF neurons during stress. Ann N Y Acad Sci 1993;697:39-52.
9. KECK ME, HATZINGER M, WOTJAK CT, LANDGRAF R, HOLSBOER F, NEUMANN ID. Ageing alters intrahypothalamic release patterns of vasopressin and oxytocin in rats. Eur J Neurosci 2000;12:1487-1494.
10. RAADSHEER FC, HOOGENDIJK WJG, STAM FC, TILDERS FJH, SWAAB DF. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 1994;60:436-444.
11. KECK ME, WIGGER A, WELT T et al. Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats: implications for pathogenesis of affective disorders. Neuropsychopharmacology 2002;26:94-105.
12. YOUNG EA, KOTUN J, HASKETT RF et al. Dissociation between pituitary and adrenal suppression to dexamethasone in depression. Arch Gen Psychiatry 1993;50:395-403.
13. HELLMAN L, NAKADA F, CURTI J et al. Cortisol is secreted episodically by normal man. J Clin Endocrinol Metab 1970;30:411-422.
14. NISHIDA S, MATSUMURA S, HORINO M, OYAMA H, TENKU A. The variations of plasma corticosterone/cortisol ratios following ACTH stimulation or dexamethasone administration in normal men. J Clin Endocrinol Metab 1977;45:585-588.
15. KARSSEN AM, MEIJER OC, VAN DER SANDT ICJ et al. Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 2001;142:2686-2694.
16. ARRIZA JL, WEINBERGER C, CERELLI G et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987;237:268-275.
17. REUL JM, DE KLOET ER. Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology 1985;117:2505-2511.
18. PATEL PD, SHERMAN TG, GOLDMAN DJ, WATSON SJ. Molecular cloning of a mineralocorticoid (type I) receptor complementary DNA from rat hippocampus. Mol Endocrinol 1989;3:1877-1885.
19. EVANS RM, ARRIZA JL. A molecular framework for the actions of glucocorticoid hormones in the nervous system. Neuron 1989;2:1105-1112.
20. PATEL PD, LOPEZ JF, LYONS DM, BURKE S, WALLACE M, SCHATZBERG AF. Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain. J Psychiatr Res 2000;34:383-392.
21. VAN EEKELEN JA, JIANG W, DE KLOET ER, BOHN MC. Distribution of the mineralocorticoid and the glucocorticoid receptor mRNAs in the rat hippocampus. J Neurosci Res 1988;21:88-94.
22. SULCOVA J, HILL M, HAMPL R, STARKA L. Age and sex related differences in serum levels of unconjugated dehydroepiandrosterone and its sulphate in normal subjects. J Endocrinol 1997;154:57-62.
23. HERBERT J. Fortnightly review. Stress, the brain, and mental illness. BMJ 1997;315:530-535.
24. HERBERT J. The age of dehydroepiandrosterone. Lancet 1995;345:1193-1194.
25. HERBERT J. Neurosteroids, brain damage, and mental illness. Exp Gerontol 1998;33:713-727.
26. CARDOUNEL A, REGELSON W, KALIMI M. Dehydroepiandrosterone protects hippocampal neurons against neurotoxin-induced cell death: mechanism of action. Proc Soc Exp Biol Med 1999;222:145-149.
27. WOLF OT, KOSTER B, KIRSCHBAUM C et al. A single administration of dehydroepiandrosterone does not enhance memory performance in young healthy adults, but immediately reduces cortisol levels. Biol Psychiatry 1997;42:845-848.
28. UEDA K, OKAMURA N, HIRAI M et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992;267:24248-24252.
29. HOFFMEYER S, BURK O, VON RICHTER O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000;97:3473-3478.
30. MEIJER OC, DE LANGE EC, BREIMER DD, DE BOER AG, WORKEL JO, DE KLOET ER. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 1998;139:1789-1793.
31. WATSON S, GALLAGHER P, RITCHIE JC, FERRIER IN, YOUNG AH. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry 2004;184:496-502.
32. SAPOLSKY R. Stress, the ageing brain and the mechanism of neuron death. Cambridge, MA: MIT Press; 1992.
33. CARROLL BJ, CURTIS GC, MENDELS J. Cerebrospinal fluid and plasma free cortisol concentrations in depression. Psychol Med 1976;6:235-244.
34. CARROLL BJ, CURTIS GC, DAVIES BM, MENDELS J, SUGERMAN AA. Urinary free cortisol excretion in depression. Psychol Med 1976;6:43-50.
35. BROUWER JP, APPELHOF BC, HOOGENDIJK WJG et al. Thyroid and adrenal axis in major depression: a controlled study in outpatients. Eur J Endocrinol 2005;152:185-191.
36. GARTSIDE SE, LEITCH MM, YOUNG AH. Altered glucocorticoid rhythm attenuates the ability of a chronic SSRI to elevate forebrain 5-HT: implications for the treatment of depression. Neuropsychopharmacology 2003;28:1572-1578.
37. SACHAR EJ, HELLMAN L, ROFFWARG HP, HALPERN FS, FUKUSHIMA DK, GALLAGHER TF. Disrupted 24-hour patterns of cortisol secretion in psychotic depression. Arch Gen Psychiatry 1973;28:19-24.
38. DEUSCHLE M, SCHWEIGER U, WEBER B et al. Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab 1997;82:234-238.
39. HALBREICH U, ASNIS GM, SHINDLEDECKER R, ZUMOFF B, NATHAN RS. Cortisol secretion in endogenous depression. I. Basal plasma levels. Arch Gen Psychiatry 1985;42:904-908.
40. LINKOWSKI P, MENDLEWICZ J, LECLERCQ R et al. The 24-hour profile of adrenocorticotropin and cortisol in major depressive illness. J Clin Endocrinol Metab 1985;61:429-438.
41. YOUNG EA, CARLSON NE, BROWN MB. Twenty-four-hour ACTH and cortisol pulsatility in depressed women. Neuropsychopharmacology 2001;25:267-276.
42. PFOHL B, SHERMAN B, SCHLECHTE J, STONE R. Pituitary-adrenal axis rhythm disturbances in psychiatric depression. Arch Gen Psychiatry 1985;42:897-903.
43. JARRETT DB, COBLE PA, KUPFER DJ. Reduced cortisol latency in depressive illness. Arch Gen Psychiatry 1983;40:506-511.
44. HALBREICH U, ASNIS GM, SHINDLEDECKER R, ZUMOFF B, NATHAN RS. Cortisol secretion in endogenous depression. II. Time-related functions. Arch Gen Psychiatry 1985;42:909-914.
45. CLAUSTRAT B, CHAZOT G, BRUN J, JORDAN D, SASSOLAS G. A chronobiological study of melatonin and cortisol secretion in depressed subjects: plasma melatonin, a biochemical marker in major depression. Biol Psychiatry 1984;19:1215-1228.
46. RUBIN R, POLAND R, LESSER I, WINSTON R, BLODGETT N. Neuroendocrine aspects of primary endogenous depression, cortisol secretory dynamics in patients and matched controls. Arch Gen Psychiatry 1987;44:328-336.
47. SHERMAN B, PFOHL B, WINOKUR G. Circadian analysis of plasma cortisol levels before and after dexamethasone administration in depressed patients. Arch Gen Psychiatry 1984;41:271-275.
48. STRICKLAND PL, DEAKIN JF, PERCIVAL C, DIXON J, GATER RA, GOLDBERG DP. Bio-social origins of depression in the community. Interactions between social adversity, cortisol and serotonin neurotransmission. Br J Psychiatry 2002;180:168-173.
49. YOUNG EA, HASKETT RF, GRUNHAUS L et al. Increased evening activation of the hypothalamic-pituitary-adrenal axis in depressed patients. Arch Gen Psychiatry 1994;51:701-707.
50. RUBIN RT, PHILLIPS JJ, SADOW TF, MCCRACKEN JT. Adrenal gland volume in major depression. Increase during the depressive episode and decrease with successful treatment. Arch Gen Psychiatry 1995;52:213-218.
51. KRISHNAN KRR, DORAISWAMY PM, LURIE SN et al. Pituitary size in depression. J Clin Endocrinol Metab 1991;72:256-259.
52. AXELSON DA, DORAISWAMY PM, BOYKO OB et al. In vivo assessment of pituitary volume with magnetic resonance imaging and systematic stereology: relationship to dexamethasone suppression test results in patients. Psychiatry Res 1992;44:63-70.
53. CARROLL BJ, FEINBERG M, GREDEN JF et al. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch Gen Psychiatry 1981;38:15-22.
54. MAGUIRE KP, SCHWEITZER I, BIDDLE N, BRIDGE S, TILLER JW. The dexamethasone suppression test: importance of dexamethasone concentrations. Biol Psychiatry 1987;22:957-967.
55. WIEDEMANN K, HOLSBOER F. The effect of dexamethasone dosage upon plasma cortisol and dexamethasone during the DST. J Affect Disord 1990;19:133-137.
56. O'SULLIVAN BT, HUNT GE, JOHNSON GF, CATERSON ID. The plasma dexamethasone window: evidence supporting its usefulness to validate dexamethasone suppression test results. Biol Psychiatry 1989;25:739-754.
57. HEUSER I, YASSOURIDIS A, HOLSBOER F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 1994;28:341-356.
58. HOLSBOER F, LAUER CJ, SCHREIBER W, KRIEG JC. Altered hypothalamic- pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology 1995;62:340-347.
59. VON BARDELEBEN U, HOLSBOER F, STALLA GK, MULLER OA. Combined administration of human corticotropinreleasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects. Life Sci 1985;37:1613-1618.
60. ZOBEL AW, NICKEL T, SONNTAG A, UHR M, HOLSBOER F, ISING M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: a prospective study. J Psychiatr Res 2001;35:83-94.
61. RIBEIRO SC, TANDON R, GRUNHAUS L, GREDEN JF. The DST as a predictor of outcome in depression: a metaanalysis. Am J Psychiatry 1993;150:1618-1629.
62. NEMEROFF CB, WIDERLOV E, BISSETTE G et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984;226:1342-1344.
63. DE BELLIS MD, GOLD PW, GERACIOTI TD, LISTWAK SJ, KLING MA. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry 1993;150:656-657.
64. GERACIOTI TD Jr, ORTH DN, EKHATOR NN, BLUMENKOPF B, LOOSEN PT. Serial cerebrospinal fluid corticotropin-releasing hormone concentrations in healthy and depressed humans. J Clin Endocrinol Metab 1992;74:1325-1330.
65. GERACIOTI TD, LOOSEN PT, ORTH DN. Low cerebrospinal fluid corticotropin-releasing hormone concentrations in eucortisolemic depression. Biol Psychiatry 1997;42:165-174.
66. WONG ML, KLING MA, MUNSON PJ et al. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci U S A 2000;97:325-330.
67. GOLD PW, CHROUSOS G, KELLNER C et al. Psychiatric implications of basic and clinical studies with corticotropin-releasing factor. Am J Psychiatry 1984;141:619-627.
68. GOLD PW, LORIAUX DL, ROY A et al. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. N Engl J Med 1986;314:1329-1335.
69. HOLSBOER F, VON BARDELEBEN U, GERKEN A, STALLA GK, MULLER OA. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N Engl J Med 1984;311:1127.
70. HOLSBOER F, GERKEN A, VON BARDELEBEN U et al. Human corticotropin- releasing hormone in depression-correlation with thyrotropin secretion following thyrotropin-releasing hormone. Biol Psychiatry 1986;21:601-611.
71. GOLD PW, LICINIO J, WONG ML, CHROUSOS GP. Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Ann N Y Acad Sci 1995;771:716-729.
72. LISANSKY J, PEAKE GT, STRASSMAN RJ et al. Augmented pituitary corticotropin response to a threshold dosage of human corticotropin-releasing hormone in depressives pretreated with metyrapone. Arch Gen Psychiatry 1989;46:641-649.
73. YOUNG EA, AKIL H, HASKETT RF, WATSON SJ. Evidence against changes in corticotroph CRF receptors in depressed patients. Biol Psychiatry 1995;37:355-363.
74. NEMEROFF CB, OWENS MJ, BISSETTE G, ANDORN AC, STANLEY M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 1988;45:577-579.
75. LEAKE A, PERRY EK, PERRY RH, FAIRBAIRN AF, FERRIER IN. Cortical concentrations of corticotropin-releasing hormone and its receptor in Alzheimer type dementia and major depression. Biol Psychiatry 1990;28:603-608.
76. HUCKS D, LOWTHER S, CROMPTON MR, KATONA CL, HORTON RW. Corticotropin-releasing factor binding sites in cortex of depressed suicides. Psychopharmacology (Berl) 1997;134:174-178.
77. RAADSHEER FC, TILDERS FJ, SWAAB DF. Similar age related increase of vasopressin colocalization in paraventricular corticotropin-releasing hormone neurons in controls and Alzheimer patients. J Neuroendocrinol 1994;6:131-133.
78. PURBA JS, HOOGENDIJK WJG, HOFMAN MA, SWAAB DF. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry 1996;53:137-143.
79. MICHAEL A, JENAWAY A, PAYKEL ES, HERBERT J. Altered salivary dehydroepiandrosterone levels in major depression in adults. Biol Psychiatry 2000;48:989-995.
80. YOUNG AH, GALLAGHER P, PORTER RJ. Elevation of the cortisol- dehydroepiandrosterone ratio in drug-free depressed patients. Am J Psychiatry 2002;159:1237-1239.
81. GOODYER IM, HERBERT J, ALTHAM PM. Adrenal steroid secretion and major depression in 8- to 16-year-olds, III. Influence of cortisol/DHEA ratio at presentation on subsequent rates of disappointing life events and persistent major depression. Psychol Med 1998;28:265-273.
82. RUSH AJ, GILES DE, SCHLESSER MA et al. The dexamethasone suppression test in patients with mood disorders. J Clin Psychiatry 1996;57:470-484.
83. RYBAKOWSKI JK, TWARDOWSKA K. The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness. J Psychiatr Res 1999;33:363-370.
84. SCHMIDER J, LAMMERS CH, GOTTHARDT U, DETTLING M, HOLSBOER F, HEUSER IJ. Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I. Biol Psychiatry 1995;38:797-802.
85. WATSON S, GALLAGHER P, FERRIER IN, YOUNG A. Post-dexamethasone arginine vasopressin levels in patients with severe mood disorders. J Psychiatr Res 2006;40:353-359.
86. KNABLE MB, TORREY EF, WEBSTER MJ, BARTKO JJ. Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium. Brain Res Bull 2004;55:651-659.
87. LOPEZ JF, LITTLE KY, LOPEZ-FIGUEROA AL, LOPEZ-FIGUEROA MO, WATSON SJ. Glucocorticoid and mineralocorticoid receptor mRNA levels in the hippocampus and prefrontal cortex of subjects with mood disorders and schizophrenia. Biol Psychiatry 2003;53:489.
88. WEBSTER MJ, KNABLE MB, O'GRADY J, ORTHMANN J, WEICKERT CS. Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol Psychiatry 2002;7:985-994.
89. WATSON S, GALLAGHER P, DEL-ESTAL D, HEARN A, FERRIER IN, YOUNG AH. Hypothalamic-pituitary-adrenal axis function in patients with chronic depression. Psychol Med 2002;32:1021-1028.
90. NELSON JC, DAVIS JM. DST studies in psychotic depression: a meta analysis. Am J Psychiatry 1997;154:1497-1503.
91. POSENER JA, DEBATTISTA C, WILLIAMS GH, CHMURA KRAEMER H, KALEHZAN BM, SCHATZBERG AF. 24-hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. Arch Gen Psychiatry 2000;57:755-760.
92. KELLER J, FLORES BH, GOMEZ RG et al. Cortisol circadian rhythm alterations in psychotic major depression. Biol Psychiatry 2006;60:275-281.
93. MAES M, SCHOTTE C, D'HONDT P et al. Biological heterogeneity of melancholia: results of pattern recognition methods. J Psychiatr Res 1991;25:95-108.
94. MAES M, CALABRESE J, MELTZER HY. The relevance of the in- versus outpatient status for studies on HPA-axis in depression: spontaneous hypercortisolism is a feature of major depressed inpatients and not of major depression per se. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:503-517.
95. ROTH M, GURNEY C, MOUNTJOY CQ. The Newcastle rating scales. Acta Psychiatr Scand Suppl 1983;310:42-54.
96. PARKER G, HADZI-PAVLOVIC D, WILHELM K et al. Defining melancholia: properties of a refined sign-based measure. Br J Psychiatry 1994;164:316-326.
97. ZIMMERMAN M, CORYELL W, PFOHL B. The validity of the dexamethasone suppression test as a marker for endogenous depression. Arch Gen Psychiatry 1986;43:347-355.
98. KLEIN HE, BENDER W, MAYR H, NIEDERSCHWEIBERER A, SCHMAUSS M. The DST and its relationship to psychiatric diagnosis, symptoms and treatment outcome. Br J Psychiatry 1984;145:591-599.
99. BROWN RP, STOLL PM, STOKES PE et al. Adrenocortical hyperactivity in depression: effects of agitation, delusions, melancholia, and other illness variables. Psychiatry Res 1988;23:167-178.
100. MITCHELL P. Validity of the CORE: I. A neuroendocrinological strategy. In: PARKER G, HADZI-PAVLOVIC D, eds. Melancholia: a disorder of movement and mood. Cambridge: Cambridge University Press, 1996: 138-148.
101. PARIANTE CM, VASSILOPOULOU K, VELAKOULIS D et al. Pituitary volume in psychosis. Br J Psychiatry 2004;185:5-10.
102. PARIANTE CM, DAZZAN P, DANESE A et al. Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study. Neuropsychopharmacology 2005;30:1923-1931.
103. GARNER B, PARIANTE CM, WOOD SJ et al. Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis. Biol Psychiatry 2005;58:417-423.
104. STEEN RG, MULL C, MCCLURE R, HAMER RM, LIEBERMAN JA. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry 2006;188:510-518.
105. PANTELIS C, VELAKOULIS D, MCGORRY PD et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003;361:281-288.
106. PORTER RJ. Editorial: The hypothalamic-pituitary-adrenal axis: a target for intervention in early psychosis? Aust N Z J Psychiatry 2006;40:722-724.
107. CHAOULOFF F. Physiopharmacological interactions between stress hormones and central serotonergic systems. Brain Res Brain Res Rev 1993;18:1-32.
108. CHAOULOFF F. Serotonin, stress and corticoids. J Psychopharmacol 2000;14:139-151.
109. DINAN TG. Glucocorticoids and the genesis of depressive illness. A psychobiological model. Br J Psychiatry 1994;164:365-371.
110. MCALLISTER-WILLIAMS RH, FERRIER IN, YOUNG AH. Mood and neuropsychological function in depression: the role of corticosteroids and serotonin. Psychol Med 1998;28:573-584.
111. MAES M, MELTZER HY. The serotonin hypothesis of major depression. In: BLOOM FE, KUPFER DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, Ltd, 1995: 933-944.
112. PORTER RJ, GALLAGHER P, WATSON S, YOUNG AH. Corticosteroid-serotonin interactions in depression: a review of the human evidence. Psychopharmacology (Berl) 2004;173:1-17.
113. PORTER RJ, GALLAGHER P, WATSON S, LUNN BS, YOUNG AH. The effects of sub-chronic administration of hydrocortisone on hormonal and psychological responses to L-tryptophan in normal male volunteers. Psychopharmacology (Berl) 2002;163:68-75.
114. PORTER RJ, MCALLISTER-WILLIAMS RH, JONES S, YOUNG AH. Effects of dexamethasone on neuroendocrine and psychological responses to L-tryptophan infusion. Psychopharmacology (Berl) 1999;143:64-71.
115. PORTER RJ, MCALLISTER-WILLIAMS RH, LUNN BS, YOUNG AH. 5-Hydroxytryptamine receptor function in man is reduced by acute administration of hydrocortisone. Psychopharmacology (Berl) 1998;139:243-250.
116. BHAGWAGAR Z, HAFIZI S, COWEN PJ. Cortisol modulation of 5-HT-mediated growth hormone release in recovered depressed patients. J Affect Disord 2002;72:249-255.
117. BHAGWAGAR Z, MONTGOMERY AJ, GRASBY PM, COWEN PJ. Lack of effect of a single dose of hydrocortisone on serotonin(1A) receptors in recovered depressed patients measured by positron emission tomography with [11C]WAY-100635. Biol Psychiatry 2003;54:890-895.
118. MONTGOMERY AJ, BENCH CJ, YOUNG AH et al. PET measurement of the influence of corticosteroids on serotonin-1A receptor number. Biol Psychiatry 2001;50:668-676.
119. SCHATZBERG AF, ROTHSCHILD AJ, LANGLAIS PJ, BIRD ED, COLE JO. A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res 1985;19:57-64.
120. ROTHSCHILD AJ, LANGLAIS PJ, SCHATZBERG AF, WALSH FX, COLE JO, BIRD ED. Dexamethasone increases plasma free dopamine in man. J Psychiatr Res 1984;18:217-223.
121. WOLKOWITZ OM, SUTTON ME, DORAN AR et al. Dexamethasone increases plasma HVA but not MHPG in normal humans. Psychiatry Res 1985;16:101-109.
122. LUPIEN SJ, GAUDREAU S, TCHITEYA BM et al. Stress-induced declarative memory impairment in healthy elderly subjects: relationship to cortisol reactivity. J Clin Endocrinol Metab 1997;82:2070-2075.
123. KIRSCHBAUM C, WOLF OT, MAY M, WIPPICH W, HELLHAMMER DH. Stress and treatment-induced elevations of cortisol levels associated with impaired declarative memory in healthy adults. Life Sci 1996;58:1475-1483.
124. BECKWITH BE, PETROS TV, SCAGLIONE C, NELSON J. Dose-dependent effects of hydrocortisone on memory in human males. Physiol Behav 1986;36:283-286.
125. FEHM-WOLFSDORF G, REUTTER K, ZENZ H, BORN J, FEHM HL. Are circadian variations in taste thresholds cortisol-dependant? J Psychophysiol 1993;7:65-72.
126. PORTER RJ, BARNETT NA, IDEY A, MCGUCKIN EA, O'BRIEN JT. Effects of hydrocortisone administration on cognitive function in the elderly. J Psychopharmacol 2002;16:65-71.
127. NEWCOMER JW, SELKE G, MELSON AK et al. Decreased memory performance in healthy humans induced by stress level cortisol treatment. Arch Gen Psychiatry 1999;56:527-533.
128. YOUNG AH, SAHAKIAN BJ, ROBBINS TW, COWEN PJ. The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers. Psychopharmacology (Berl) 1999;145:260-266.
129. MAURI M, SINFORIANI E, BONO G et al. Memory impairment in Cushing's disease. Acta Neurol Scand 1993;87:52-55.
130. STARKMAN MN, SCHTEINGART DE. Neuropsychiatric manifestations of patients with Cushing's syndrome. Relationship to cortisol and adrenocorticotropic hormone levels. Arch Intern Med 1981;141:215-219.
131. DE QUERVAIN DJ, ROOZENDAAL B, NITSCH RM, MCGAUGH JL, HOCK C. Acute cortisone administration impairs retrieval of long-term declarative memory in humans. Nat Neurosci 2000;3:313-314.
132. DE QUERVAIN DJ, HENKE K, AERNI A et al. Glucocorticoid-induced impairment of declarative memory retrieval is associated with reduced blood flow in the medial temporal lobe. Eur J Neurosci 2003;17:1296-1302.
133. LUPIEN SJ, GILLIN CJ, HAUGER RL. Working memory is more sensitive than declarative memory to the acute effects of corticosteroids: a dose-response study in humans. Behav Neurosci 1999;113:420-430.
134. JELICI M, GERAERTS E, MERCKELBACH H, GUERRIERI R. Acute stress enhances memory for emotional words, but impairs memory for neutral words. Int J Neurosci 2004;114:1343-1351.
135. WOLF OT, KUHLMANN S, BUSS C, HELLHAMMER DH, KIRSCHBAUM C. Cortisol and memory retrieval in humans: influence of emotional valence. Ann N Y Acad Sci 2004;1032:195-197.
136. KUHLMANN S, WOLF OT. Arousal and cortisol interact in modulating memory consolidation in healthy young men. Behav Neurosci 2006;120:217-223.
137. MAHEU FS, COLLICUTT P, KORNIK R, MOSZKOWSKI R, LUPIEN SJ. The perfect time to be stressed: a differential modulation of human memory by stress applied in the morning or in the afternoon. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1281-1288.
138. O'BRIEN JT, SCHWEITZER I, AMES D, TUCKWELL V, MASTWYK M. Cortisol suppression by dexamethasone in the healthy elderly: effects of age, dexamethasone levels, and cognitive function. Biol Psychiatry 1994;36:389-394.
139. MITCHELL AJ. The contribution of hypercortisolaemia to the cognitive decline of geriatric depression. Int J Geriatr Psychiatry 1995;10:401-409.
140. WAUTHY J, ANSSEAU M, VON FRENCKELL R, MORMONT C, LEGROS JJ. Memory disturbances and dexamethasone suppression test in major depression. Biol Psychiatry 1991;30:736-738.
141. RUBINOW DR, POST RM, SAVARD R, GOLD PW. Cortisol hypersecretion and cognitive impairment in depression. Arch Gen Psychiatry 1984;41:279-283.
142. PORTER RJ, GALLAGHER P, THOMPSON JM, YOUNG AH. Neurocognitive impairment in drug-free patients with major depressive disorder. Br J Psychiatry 2003;182:214-220.
143. WATSON S, THOMPSON JM, RITCHIE JC, NICOL FERRIER I, YOUNG AH. Neuropsychological impairment in bipolar disorder: the relationship with glucocorticoid receptor function. Bipolar Disord 2006;8:85-90.
144. GOULD E, MCEWEN BS. Neuronal birth and death. Curr Opin Neurobiol 1993;3:676-682.
145. BROWN ES, J WOOLSTON D, FROL A et al. Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy. Biol Psychiatry 2004;55:538-545.
146. STARKMAN MN, GIORDANI B, GEBARSKI SS, BERENT S, SCHORK MA, SCHTEINGART DE. Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease. Biol Psychiatry 1999;46:1595-1602.
147. VYTHILINGAM M, VERMETTEN E, ANDERSON GM et al. Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biol Psychiatry 2004;56:101-112.
148. O'BRIEN JT, LLOYD A, MCKEITH I, GHOLKAR A, FERRIER N. A longitudinal study of hippocampal volume, cortisol levels, and cognition in older depressed subjects. Am J Psychiatry 2004;161:2081-2090.
149. BERNE RM, LEVY MN. Physiology. 4th edn. St Louis: Mosby Inc., 1998.
150. THAKORE JH, RICHARDS PJ, REZNEK RH, MARTIN A, DINAN TG. Increased intra-abdominal fat deposition in patients with major depressive illness as measured by computed tomography. Biol Psychiatry 1997;41:1140-1142.
151. WEBER-HAMANN B, HENTSCHEL F, KNIEST A et al. Hypercortisolemic depression is associated with increased intra-abdominal fat. Psychosom Med 2002;64:274-277.
152. VRKLJAN M, THALLER V, LOVRICEVIC I et al. Depressive disorder as possible risk factor of osteoporosis. Coll Antropol 2001;25:485-492.
153. O'BRIEN SM, SCOTT LV, DINAN TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 2004;19:397-403.
154. PEPIN MC, BEAULIEU S, BARDEN N. Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Brain Res Mol Brain Res 1989;6:77-83.
155. MCQUADE R, YOUNG AH. Future therapeutic targets in mood disorders: the glucocorticoid receptor. Br J Psychiatry 2000;177:390-395.
156. BARDEN N. Regulation of corticosteroid receptor gene expression in depression and antidepressant action. J Psychiatry Neurosci 1999;24:25-39.
157. SECKL JR, FINK G. Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology 1992;55:621-626.
158. ROSSBY SP, NALEPA I, HUANG M et al. Norepinephrine-independent regulation of GRII mRNA in vivo by a tricyclic antidepressant. Brain Res 1995;687:79-82.
159. PARIANTE CM. Glucocorticoid receptor function in vitro in patients with major depression. Stress 2004;7:209-219.
160. PARIANTE CM, THOMAS SA, LOVESTONE S, MAKOFF A, KERWIN RW. Do antidepressants regulate how cortisol affects the brain? Psychoneuroendocrinology 2004;29:423-447.
161. PARIANTE CM. The glucocorticoid receptor: part of the solution or part of the problem? J Psychopharmacol 2006;20:79-84.
162. GALLAGHER P, YOUNG AH. Mifepristone (RU-486) treatment of depression and psychosis: a review of the therapeutic implications. Neuropsychiatric Dis Treat 2006;2:33-42.
163. PARIANTE CM. Depression, stress and the adrenal axis. J Neuroendocrinol 2003;15:811-812.
164. GREDEN JF, GARDNER R, KING D, GRUNHAUS L, CARROLL BJ, KRONFOL Z. Dexamethasone suppression tests in antidepressant treatment of melancholia. The process of normalization and test-retest reproducibility. Arch Gen Psychiatry 1983;40:493-500.
165. HOLSBOER-TRACHSLER E, STOHLER R, HATZINGER M. Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression. Psychiatry Res 1991;38:163-171.
166. INDER WJ, PRICKETT TC, MULDER RT, DONALD RA, JOYCE PR. Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine. Psychopharmacology (Berl) 2001;156:73-78.
167. JAHN H, SCHICK M, KIEFER F, KELLNER M, YASSOURIDIS A, WIEDEMANN K. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry 2004;61:1235-1244.
168. ARANA GW, FORBES RA. Dexamethasone for the treatment of depression: a preliminary report J Clin Psychiatry 1991;52:304-306.
169. ARANA GW, SANTOS AB, LARAIA MT et al. Dexamethasone for the treatment of depression: a randomized, placebo-controlled, double-blind trial. Am J Psychiatry 1995;152:265-267.
170. O'DWYER AM, LIGHTMAN SL, MARKS MN, CHECKLEY SA. Treatment of major depression with metyrapone and hydrocortisone. J Affect Disord 1995;33:123-128.
171. WOLKOWITZ OM, REUS VI, CHAN T et al. Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biol Psychiatry 1999;45:1070-1074.
172. GHADIRIAN AM, ENGELSMANN F, DHAR V et al. The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment. Biol Psychiatry 1995;37:369-375.
173. DINAN TG, LAVELLE E, COONEY J et al. Dexamethasone augmentation in treatment-resistant depression. Acta Psychiatr Scand 1997;95:58-61.
174. HOYBERG O, WIK G, MEHTONEN OP, PEETERS BW, SENNEF C. ORG 34517, a selective glucocrticoid receptor antagonist with potent antidepressant activity: first clinical results. Int J Neuropsychopharmacol 2002;5:S148.
175. WOLKOWITZ OM, REUS VI. Treatment of depression with antiglucocorticoid drugs. Psychosom Med 1999;61:698-711.
176. SONINO N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987;317:812-818.
177. ZOBEL AW, NICKEL T, KUNZEL HE et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000;34:171-181.
178. BLOCH M, SCHMIDT PJ, DANACEAU MA, ADAMS LF, RUBINOW DR. Dehydroepiandrosterone treatment of midlife dysthymia. Biol Psychiatry 1999;45:1533-1541.
179. SCHMIDT PJ, DALY RC, BLOCH M et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 2005;62:154-162.
180. HUPPERT FA, VAN NIEKERK JK. Dehydroepiandrosterone (DHEA) supplementation for cognitive function. Cochrane Database Syst Rev 2001;2:CD000304.
181. MURPHY BE, FILIPINI D, GHADIRIAN AM. Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486. J Psychiatry Neurosci 1993;18:209-213.
182. BELANOFF JK, FLORES BH, KALEZHAN M, SUND B, SCHATZBERG AF. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 2001;21:516-521.
183. BELANOFF JK, ROTHSCHILD AJ, CASSIDY F et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 2002;52:386-392.
184. SIMPSON GM, EL SHESHAI A, LOZA N et al. An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression. J Clin Psychiatry 2005;66:598-602.
185. DEBATTISTA C, BELANOFF J, GLASS S et al. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol Psychiatry 2006 Aug 4; [Epub ahead of print].
186. YOUNG AH, GALLAGHER P, WATSON S, DEL-ESTAL D, OWEN BM, NICOL FERRIER I. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 2004;29:1538-1545.
187. MACKIN P, GALLAGHER P, FROOM K, GEDDES J, YOUNG A. Antiglucocorticoid treatments in mood disorders: efficacy and safety [protocol]. Cochrane Database Syst Rev 2005;1.
188. BACHMANN CG, LINTHORST AC, HOLSBOER F, REUL JM. Effect of chronic administration of selective glucocorticoid receptor antagonists on the rat hypothalamic-pituitary-adrenocortical axis. Neuropsychopharmacology 2003;28:1056-1067.
189. YOUNG EA, LOPEZ JF, MURPHY-WEINBERG V, WATSON SJ, AKIL H. Mineralocorticoid receptor function in major depression. Arch Gen Psychiatry 2003;60:24-28.
190. JURUENA MF, PAPADOPOULOS A, CLEARE AJ, POON L, LIGHTMAN S, PARIANTE CM. Treatment resistant depression: different response to dexamethasone and prednisolone test. 2005 ENCP Hot Topic Award. Eur Neuropsychopharmacol 2005;15:414.
191. LUPIEN SJ, MCEWEN BS. The acute effects of corticosteroids on cognition: integration of animal and human model studies. Brain Res Brain Res Rev 1997;24:1-27.